Is EHC a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Encompass Health (EHC) rests on De novo hospitals and bed additions: Growth here is physical, not promotional. The bear case rests on encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Analysts covering it publish targets from $142.00 to $177.00 against a $142.11 share price on November 16, 2026, so even the professionals disagree by 22% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
EHC key stats
At $142.11 on November 16, 2026, Encompass Health (EHC) has a market cap of $13.9B, a P/E of 22.7 on trailing earnings (20.6 on forward earnings) and a dividend yield of 0.59%.
- Market cap
- $13.9B
- P/E (trailing)
- 22.7
- P/E (forward)
- 20.6
- EPS (trailing 12 months)
- $6.25
- Price to book
- 5.2
- Dividend yield
- 0.59%
- Beta
- 0.67
Market cap, P/E and yield are measured at the $142.11 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Encompass Health (EHC)?
The last two weeks for Encompass Health, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- EHC closed at $142.11 on November 16, 2026, up 0.7% over the past five trading days (from $141.15).
- On November 6, 2026, Encompass Health filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
- On November 3, 2026, Encompass Health filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. As of the second quarter of 2026 it operated 176 hospitals (about 178 by October 2026) across 39 states and Puerto Rico, which makes it the largest operator in the category by a wide margin. Medicare fee-for-service is its dominant payer, and under the IRF prospective payment system it is paid a set amount per discharge based on the patient's condition and complexity, so revenue is essentially discharges multiplied by net revenue per discharge. A portion of its hospitals are structured as joint ventures with acute-care health systems, which brings referral flow and shared construction capital while handing a slice of consolidated profit to noncontrolling interests. The company became a pure-play rehabilitation operator in 2022 when it spun off its home health and hospice arm as Enhabit. The investment picture is unusually mechanical for a healthcare name. Second-quarter 2026 revenue was about $1.60 billion, up 9.6 percent, with adjusted EBITDA of roughly $348 million and adjusted earnings per share of about $1.55. Discharges rose 5.6 percent while same-store discharges rose 2.8 percent, so a little under half the volume growth came from capacity that did not exist a year ago. Management raised full-year 2026 guidance to $6.41 billion to $6.49 billion of revenue, $1.365 billion to $1.395 billion of adjusted EBITDA, and adjusted EPS of $6.02 to $6.25. As of October 16, 2026 the shares closed near $128 for a market capitalization near $12.6 billion, about 21 times the midpoint of guided adjusted earnings and about 19 times the 2027 consensus. The stock is up about 20 percent in 2026 but only about 4 percent over one year, because the 52-week range includes the post-2025 low near $93. What the multiple is really pricing is whether the new-hospital pipeline keeps converting, whether annual Medicare rate updates stay ahead of wage inflation, and how much of the patient pool Medicare Advantage plans redirect to cheaper post-acute settings. Since the second-quarter report the build-out has continued. On October 6, 2026 Encompass opened a 50-bed hospital in Bangor, its first wholly owned hospital in Maine, and in September it announced its first small-format hospital: a 24-bed satellite in Conroe, Texas, expected to open in late 2027 and run off the existing hospital in The Woodlands. The company's 2026 plan now calls for eight new hospitals totaling 389 beds plus 150 to 200 beds added to existing sites. Q2 adjusted EPS of $1.55 beat the roughly $1.48 consensus, the fourth beat in a row, and third-quarter results are scheduled for October 28, with consensus near $1.36 of EPS on about $1.60 billion of revenue.
The bull case: what would have to be true for $177.00
The most optimistic published target on EHC is $177.00, +24.6% from the $142.11 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. De novo hospitals and bed additions
Growth here is physical, not promotional. Through the first half of 2026 Encompass opened three hospitals totaling 139 beds and added 54 beds to existing facilities, with five more hospitals and roughly 100 to 150 additional beds planned before year-end. Beds bolted onto an existing hospital carry high incremental margins because the fixed overhead is already paid for, while a brand-new hospital loses money for several quarters before it ramps. The 2026 plan totals eight new hospitals and 389 beds, including the 50-bed Bangor, Maine hospital opened October 6, 2026. A newer lever is the small-format satellite: a 24-bed hospital in Conroe, Texas, due in late 2027, will share management, referrals and payer contracts with the parent hospital in The Woodlands, a lighter way to reach nearby growth markets.
2. Demographics against a supply-constrained niche
The patient pool grows with the over-75 population, and stroke and fracture volumes track it closely. Building a competing IRF is slow: certificate-of-need laws apply in some states, Medicare's 60 percent rule constrains what kind of patients a facility can admit, and the clinical staffing model is hard to assemble. That combination limits how quickly supply can respond to demand in any given market.
3. Administered pricing that has been keeping up
The Medicare fee-for-service rate is set by CMS rather than negotiated. For fiscal 2027 CMS finalized a 2.3 percent IRF payment update, a 3.2 percent market basket less a 0.9 point productivity adjustment, which took effect in October 2026. Encompass has also been growing net revenue per discharge faster than that, about 3.9 percent in the second quarter, largely on higher patient acuity and mix.
4. Labor is the binding constraint
Nurses and therapists, not construction, decide how fast a hospital opens and how full it runs. Salaries and benefits were about $820 million in the second quarter, a little over half of revenue, so a point of wage inflation matters more than almost anything else on the income statement. Management tracks employees per occupied bed as the productivity measure, and the joint-venture partners often help with local recruiting.
The bear case: what would have to be true for $142.00
The most pessimistic published target is $142.00, -0.1% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Encompass Health is worth if the risks below bite instead of the drivers above.
Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026. Finally, the balance sheet carries about $2.84 billion of debt against little cash, and capital spending on new hospitals kept trailing free cash flow to about $230 million on $1.21 billion of operating cash flow, so the build-out depends on continued access to financing.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding EHC already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on EHC
12 analysts cover EHC, with an average target of $156.08 (+9.8% against $142.11) and a split of 13 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the EHC forecast and price target page.
How is EHC valued?
Market cap, P/E and dividend yield at today's price are in the EHC key stats above. The business figures below come from Encompass Health's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$6.21B
- Q2 2026 revenue: ~$1.60B, up ~9.6%
- Q2 2026 adjusted EPS: ~$1.55 (est. ~$1.48)
- Net income (TTM): ~$604M (~10% margin)
- FY2026 adjusted EBITDA guidance: ~$1.365B to $1.395B
As of October 2026: As of October 16, 2026 the shares traded near $128, giving a market capitalization around $12.6 billion against trailing revenue of roughly $6.21 billion. Guided 2026 adjusted EPS of $6.02 to $6.25 puts the stock at about 21 times the midpoint and about 19 times the 2027 consensus of $6.68, a premium to most hospital operators and a reflection of the visible bed pipeline rather than of any margin inflection. The stock has risen about 14 percent in three months to near a 52-week high, so the October 28 report arrives with less valuation cushion than in August.
How do you decide if EHC is a buy?
Whether EHC is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold EHC indirectly through an index or sector ETF before adding more.
What would change your mind on EHC
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: De novo hospitals and bed additions stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the EHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about EHC against your real portfolio and see your actual exposure before deciding.
Your questions about Encompass Health
Ask Walnut's AI anything about EHC and see how it fits what you own.
FAQ
Is EHC a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on De novo hospitals and bed additions, with revenue (ttm) at ~$6.21B. The bear case rests on encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Analysts covering it are spread from $142.00 to $177.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell EHC?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $142.00, -0.1% from the $142.11 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for EHC?
+
De novo hospitals and bed additions. Growth here is physical, not promotional. The most optimistic analyst target on EHC is $177.00, +24.6% from the $142.11 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for EHC?
+
Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026. Finally, the balance sheet carries about $2.84 billion of debt against little cash, and capital spending on new hospitals kept trailing free cash flow to about $230 million on $1.21 billion of operating cash flow, so the build-out depends on continued access to financing. The most pessimistic published target is $142.00, -0.1% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Encompass Health do?
+
The largest US operator of inpatient rehabilitation hospitals, growing by adding beds and opening new hospitals, paid mostly by Medicare.
What would have to change for EHC to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (De novo hospitals and bed additions) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Encompass Health do?
+
It operates inpatient rehabilitation hospitals, 176 of them across 39 states and Puerto Rico as of mid-2026 and about 178 by October 2026. Patients arrive after a stroke, hip fracture, brain or spinal cord injury, or major surgery, and receive intensive physician-supervised therapy before returning home. Medicare is the dominant payer, and Encompass is the largest operator in this category in the United States.
What is an inpatient rehabilitation facility?
+
An IRF is a hospital-level setting for patients who need intensive rehabilitation, generally around three hours of therapy a day, under daily physician oversight and 24-hour rehabilitation nursing. It sits between an acute-care hospital and home. Medicare pays IRFs under their own prospective payment system, a fixed amount per discharge set by the patient's condition, age and complexity rather than by length of stay.
What is the Medicare 60 percent rule?
+
It requires that at least 60 percent of a rehabilitation hospital's patients have one of 13 qualifying conditions, including stroke, hip fracture, brain injury, spinal cord injury and amputation. A facility that stays above the threshold is paid under the IRF system. One that falls below is paid as a general acute-care hospital instead, which is a materially worse rate, so compliance is managed closely.
Walnut is informational, not investment advice, and gives no verdict on EHC. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.